Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$69.06−5.12 (-6.90%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield –
Inhibrx Biosciences cash
Cash and short-term investments held at the end of each period.
Inhibrx Biosciences's cash was $199.47M at Sep 30, 2026. For fiscal 2025 it was $124.22M, down 18.6% from the year before. The highest annual figure on record is $277.92M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.22M | -18.6% |
| FY2024 | Dec 31, 2024 | $152.60M | -45.1% |
| FY2023 | Dec 31, 2023 | $277.92M | +1.5% |
| FY2022 | Dec 31, 2022 | $273.87M | +108.6% |
| FY2021 | Dec 31, 2021 | $131.30M | +2.0% |
| FY2020 | Dec 31, 2020 | $128.66M | +1014.9% |
| FY2019 | Dec 31, 2019 | $11.54M | +448.7% |
| FY2018 | Dec 31, 2018 | $2.10M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $199.47M | +30.3% |
| Q2 FY2026 | Jun 30, 2026 | $133.34M | -28.5% |
| Q1 FY2026 | Mar 31, 2026 | $161.66M | -25.3% |
| Q4 FY2025 | Dec 31, 2025 | $124.22M | -18.6% |
| Q3 FY2025 | Sep 30, 2025 | $153.09M | -22.0% |
| Q2 FY2025 | Jun 30, 2025 | $186.57M | -17.8% |
| Q1 FY2025 | Mar 31, 2025 | $216.52M | -14.2% |
| Q4 FY2024 | Dec 31, 2024 | $152.60M | -45.1% |
| Q3 FY2024 | Sep 30, 2024 | $196.33M | -41.8% |
| Q2 FY2024 | Jun 30, 2024 | $226.86M | +17.9% |
| Q1 FY2024 | Mar 31, 2024 | $252.48M | +7.8% |
| Q4 FY2023 | Dec 31, 2023 | $277.92M | +1.5% |
| Q3 FY2023 | Sep 30, 2023 | $337.33M | +130.9% |
| Q2 FY2023 | Jun 30, 2023 | $192.49M | +9.1% |
| Q1 FY2023 | Mar 31, 2023 | $234.25M | +63.3% |
| Q4 FY2022 | Dec 31, 2022 | $273.87M | +108.6% |
| Q3 FY2022 | Sep 30, 2022 | $146.07M | +29.6% |
| Q2 FY2022 | Jun 30, 2022 | $176.39M | +40.3% |
| Q1 FY2022 | Mar 31, 2022 | $143.47M | +32.9% |
| Q4 FY2021 | Dec 31, 2021 | $131.30M | +2.0% |
| Q3 FY2021 | Sep 30, 2021 | $112.70M | -11.7% |
| Q2 FY2021 | Jun 30, 2021 | $125.73M | +2132.4% |
| Q1 FY2021 | Mar 31, 2021 | $107.99M | +25131.3% |
| Q4 FY2020 | Dec 31, 2020 | $128.66M | +1014.9% |
| Q3 FY2020 | Sep 30, 2020 | $127.67M | +426.3% |
| Q2 FY2020 | Jun 30, 2020 | $5.63M | +167.8% |
| Q1 FY2020 | Mar 31, 2020 | $428.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $11.54M | – |
| Q3 FY2019 | Sep 30, 2019 | $24.26M | – |
| Q4 FY2018 | Dec 31, 2018 | $2.10M | – |
See a number that looks wrong?